Clinical Trial Update: AZD3293 Thorough QT Study in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 thorough QT study of lanabecestat (AZD3293) in healthy male volunteers to assess cardiac repolarization safety; the study sponsored by AstraZeneca has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• lanabecestat (lanabecestat)

Snippet

Sponsor: AstraZeneca | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED